Rhythm Pharmaceuticals, Inc. (RYTM) announced on Friday that it anticipates its full-year product revenue to reach approximately $130 million, a notable increase from the $77.4 million reported the previous year.
In the fourth quarter, the company projects revenue from IMCIVREE (setmelanotide) sales to be roughly $42 million, which represents a 26% rise compared to the preceding quarter.
Additionally, Rhythm Pharmaceuticals stated that it remains on schedule to release topline results from the pivotal Phase 3 trial of setmelanotide, aimed at addressing acquired Hypothalamic Obesity (HO), in the first half of 2025.
The company is expected to announce its fourth-quarter results toward the end of February.
